http://jcps.bjmu.edu.cn

中国药学(英文版) ›› 2014, Vol. 23 ›› Issue (2): 83-88.DOI: 10.5246/jcps.2014.02.010

• 【研究论文】 • 上一篇    下一篇

肿瘤转移靶向肽修饰的阿霉素脂质体对高转移性乳腺癌细胞的靶向特异性研究

杨芳, 何冰, 代文兵, 王学清, 王坚成, 张烜, 张强*   

  1. 北京大学医学部 天然药物及仿生药物国家重点实验室; 药学院 药剂学系, 北京 100191
  • 收稿日期:2013-05-10 修回日期:2013-05-27 出版日期:2014-02-15 发布日期:2014-01-25
  • 通讯作者: 张强*
  • 作者简介:*Corresponding author. Tel.: +86-10-82802791; E-mail: zqdodo@bjmu.edu.cn
  • 基金资助:
    National Natural Science Foundation of China (Grant No. 81130059) and the National Research Fund for Fundamental Key Project (Grant No. 2009CB930300).

A study of liposomal doxorubicin modified by tumor metastasis targeting peptide for its specificity to highly metastatic breast cancer cells

Fang Yang, Bing He, Wenbing Dai, Xueqing Wang, Jiancheng Wang, Xuan Zhang, Qiang Zhang*   

  1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
  • Received:2013-05-10 Revised:2013-05-27 Online:2014-02-15 Published:2014-01-25
  • Contact: Qiang Zhang*
  • About author:*Corresponding author. Tel.: +86-10-82802791; E-mail: zqdodo@bjmu.edu.cn
  • Supported by:
    National Natural Science Foundation of China (Grant No. 81130059) and the National Research Fund for Fundamental Key Project (Grant No. 2009CB930300).

摘要:

肿瘤转移日渐成为肿瘤治疗的重要靶标。本研究采用肿瘤转移靶向肽(TMT)与脂质材料(PEG-DSPE)偶联获得靶向化合物(TMT-PEG-DSPE),用以构建靶向阿霉素脂质体(TMT-LS-DOX)。结果表明, TMT-LS-DOX呈现出良好的药剂学性质。选用高转移性乳腺癌细胞(MDA-MB-435SMDA-MB-231)对该转移特异性递送系统进行评价, 采用非转移性乳腺癌细胞(MCF-7)作为对照。游离TMT多肽浓度达100 μg/mL时仍未显示出细胞毒性。与MCF-7相比, MDA-MB-435SMDA-MB-231细胞对TMT-LS-DOX摄取增加, 并经受体竞争性实验证明该促进作用由TMT介导。因此, TMT修饰的纳米载体可能成为增加化疗药物对高转移性乳腺癌特异性的一种新策略。

关键词: 高转移性乳腺癌, 肿瘤转移靶向肽, 脂质体, 阿霉素

Abstract:

Tumor metastasis emerges as a crucial target for tumor therapy. In this study, a tumor metastasis targeting peptide (TMT) was conjugated to a lipid material (PEG-DSPE) to obtain the targeting compound (TMT-PEG-DSPE), which was used to construct the targeted liposomal doxorubicin (TMT-LS-DOX). We showed that TMT-LS-DOX presented satisfactory pharmaceutical characteristics. This metastasis-specific delivery system was tested in two highly metastatic breast cancer cell lines (MDA-MB-435S and MDA-MB-231) with a non-metastatic breast cancer cell line (MCF-7) as the control. The free TMT peptide itself showed no cytotoxicity even at the concentration of 100 μg/mL. Importantly, the enhanced cellular uptake of TMT-LS-DOX to both MDA-MB-435S and MDA-MB-231 cell lines was demonstrated as compared to MCF-7 cells, via a TMT-mediated mechanism demonstrated by a receptor competition study. In conclusion, the TMT modified nanocarriers might provide a strategy to enhance the specificity of chemotherapeutic agents to highly metastatic breast cancer.

Key words: Highly metastatic breast cancer, Tumor metastasis targeting peptide, Liposomes, Doxorubicin

中图分类号: 

Supporting: National Natural Science Foundation of China (Grant No. 81130059) and the National Research Fund for Fundamental Key Project (Grant No. 2009CB930300).